Nebulized aminoglycosides for ventilator-associated pneumonia: Methodological considerations and lessons from...

Area of Science:

• Pharmacology
• Infectious Diseases
• Pulmonary Medicine

Background:

• Aminoglycosides are concentration-dependent bactericidal antibiotics.
• Intravenous administration shows poor lung penetration and significant systemic toxicity (renal, ototoxicity).
• Current guidelines restrict aminoglycoside use to 5 days due to toxicity concerns.

Purpose of the Study:

• To evaluate the efficacy and pharmacokinetics of nebulized aminoglycosides in treating lung infections.
• To compare lung penetration and systemic toxicity of nebulized versus intravenous aminoglycosides.
• To investigate the impact of lung aeration and injury on aminoglycoside distribution.

Main Methods:

• Experimental studies in anesthetized, mechanically ventilated sheep and pigs with inoculation pneumonia.
• Administration of high-dose nebulized aminoglycosides.
• Assessment of lung tissue concentrations and bacterial killing.
• Evaluation of systemic diffusion and toxicity.
• Utilized lung microdialysis for accurate pharmacokinetic assessment.

Main Results:

• Nebulized aminoglycosides achieved rapid and potent bacterial killing in infected lung parenchyma.
• Alveolar-capillary membrane injury increased systemic diffusion of nebulized aminoglycosides.
• Loss of lung aeration decreased lung penetration but still achieved bactericidal concentrations in consolidated regions.
• Lung microdialysis confirmed accurate lung pharmacokinetic assessment, unlike epithelial lining fluid.

Conclusions:

• Nebulized aminoglycosides can achieve bactericidal concentrations in infected lung tissue, even in non-aerated regions.
• The study challenges the assumption that nebulization inherently protects against systemic toxicity.
• Lung microdialysis is crucial for accurate pharmacokinetic evaluation of nebulized antibiotics in lung infections.
• A call for an international research network (LUMINA) to conduct further studies on nebulized antibiotics in ventilator-associated pneumonia was made.